452 related articles for article (PubMed ID: 31552601)
41. Effectiveness and safety of vedolizumab and infliximab in biologic-naïve patients with moderate-to-severe ulcerative colitis: A multicenter, retrospective cohort study.
Meng RP; Huang BB; Wei YL; Lyu L; Yang H; Liu C; Zhou HL; Liao XP; Zhou JY; Xie X
J Dig Dis; 2024 Apr; 25(4):230-237. PubMed ID: 38764418
[TBL] [Abstract][Full Text] [Related]
42. A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis.
Stawowczyk E; Kawalec P
Pharmacoeconomics; 2018 Apr; 36(4):419-434. PubMed ID: 29260508
[TBL] [Abstract][Full Text] [Related]
43. Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn's Disease in China.
Zhou T; Sheng Y; Guan H
Adv Ther; 2021 Aug; 38(8):4233-4245. PubMed ID: 34089502
[TBL] [Abstract][Full Text] [Related]
44. Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain.
Taxonera C; de Andrés-Nogales F; García-López S; Sánchez-Guerrero A; Menchén B; Peral C; Cábez A; Gómez S; López-Ibáñez de Aldecoa A; Casado MÁ; Menchén L
Expert Rev Pharmacoecon Outcomes Res; 2022 Jan; 22(1):73-83. PubMed ID: 33615953
[TBL] [Abstract][Full Text] [Related]
45. Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective.
Goeree R; Chiva-Razavi S; Gunda P; Jain M; Jugl SM
J Med Econ; 2019 Jan; 22(1):45-52. PubMed ID: 30346844
[TBL] [Abstract][Full Text] [Related]
46. The biologics of ulcerative colitis.
Macaluso FS; Renna S; Orlando A; Cottone M
Expert Opin Biol Ther; 2017 Feb; 17(2):175-184. PubMed ID: 27960557
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment.
Bouhnik Y; Atreya R; Casey D; Górecki M; Baik D; Yoon SW; Kwon TS; Jang M
Inflamm Bowel Dis; 2023 Jun; 29(6):898-913. PubMed ID: 35942647
[TBL] [Abstract][Full Text] [Related]
48. Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naïve and biologic-experienced patients with ulcerative colitis in France.
Oppe M; Muresan B; Chan K; Radu X; Schultz BG; Turpin RS; Nucit A; Fenu E
Expert Rev Pharmacoecon Outcomes Res; 2023 Feb; 23(2):205-213. PubMed ID: 36541707
[TBL] [Abstract][Full Text] [Related]
49. Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada.
Fenu E; Lukyanov V; Acs A; Radu X; Stypa S; Fischer A; Marshall JK; Oppe M
Pharmacoecon Open; 2022 Jul; 6(4):519-537. PubMed ID: 35474178
[TBL] [Abstract][Full Text] [Related]
50. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
[TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness analysis of abrocitinib compared with standard of care in adult moderate-to-severe atopic dermatitis in Japan.
Tanaka A; Yuasa A; Kamei K; Nagano M; Murofushi T; Bjerke A; Nakamura K; Ikeda S
J Dermatol; 2024 Jun; 51(6):759-771. PubMed ID: 38650307
[TBL] [Abstract][Full Text] [Related]
52. Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands.
Gherardi A; Roze S; Kuijvenhoven J; Ghatnekar O; Yip Sonderegger YL
J Med Econ; 2018 Sep; 21(9):869-877. PubMed ID: 29857775
[TBL] [Abstract][Full Text] [Related]
53. Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK.
Emery P; Van Keep M; Beard S; Graham C; Miles L; Jugl SM; Gunda P; Halliday A; Marzo-Ortega H
Pharmacoeconomics; 2018 Aug; 36(8):1015-1027. PubMed ID: 29797186
[TBL] [Abstract][Full Text] [Related]
54. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis.
Jairath V; Chan K; Lasch K; Keeping S; Agboton C; Blake A; Patel H
Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):711-722. PubMed ID: 33599181
[No Abstract] [Full Text] [Related]
55. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis.
Thorlund K; Druyts E; Mills EJ; Fedorak RN; Marshall JK
J Crohns Colitis; 2014 Jul; 8(7):571-81. PubMed ID: 24491514
[TBL] [Abstract][Full Text] [Related]
56. Real-world effectiveness of ustekinumab and vedolizumab in TNF-exposed pediatric patients with ulcerative colitis.
Patel PV; Zhang A; Bhasuran B; Ravindranath VG; Heyman MB; Verstraete SG; Butte AJ; Rosen MJ; Rudrapatna VA;
J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1126-1134. PubMed ID: 38482890
[TBL] [Abstract][Full Text] [Related]
57. Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis.
Dignass AU; Siegmund B; Goertz R; Schneidewind G; Fanter L
Scand J Gastroenterol; 2019 Feb; 54(2):178-187. PubMed ID: 30735443
[TBL] [Abstract][Full Text] [Related]
58. First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.
Singh S; Murad MH; Fumery M; Dulai PS; Sandborn WJ
Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2179-2191.e6. PubMed ID: 31945470
[TBL] [Abstract][Full Text] [Related]
59. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
60. Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand.
Phisalprapa P; Kositamongkol C; Limsrivilai J; Aniwan S; Charatcharoenwitthaya P; Pisespongsa P; Kitiyakara T; Treepongkaruna S; Chaiyakunapruk N
J Med Econ; 2020 Nov; 23(11):1302-1310. PubMed ID: 32729347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
